GB0610183D0 - Treatment of neurodegenerative diseases - Google Patents

Treatment of neurodegenerative diseases

Info

Publication number
GB0610183D0
GB0610183D0 GBGB0610183.6A GB0610183A GB0610183D0 GB 0610183 D0 GB0610183 D0 GB 0610183D0 GB 0610183 A GB0610183 A GB 0610183A GB 0610183 D0 GB0610183 D0 GB 0610183D0
Authority
GB
United Kingdom
Prior art keywords
treatment
neurodegenerative diseases
neurodegenerative
diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0610183.6A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxford University Innovation Ltd
Original Assignee
Oxford University Innovation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxford University Innovation Ltd filed Critical Oxford University Innovation Ltd
Priority to GBGB0610183.6A priority Critical patent/GB0610183D0/en
Publication of GB0610183D0 publication Critical patent/GB0610183D0/en
Priority to PCT/GB2007/001900 priority patent/WO2007135426A2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0610183.6A 2006-05-23 2006-05-23 Treatment of neurodegenerative diseases Ceased GB0610183D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB0610183.6A GB0610183D0 (en) 2006-05-23 2006-05-23 Treatment of neurodegenerative diseases
PCT/GB2007/001900 WO2007135426A2 (en) 2006-05-23 2007-05-23 Treatment of neurodegeneratives diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0610183.6A GB0610183D0 (en) 2006-05-23 2006-05-23 Treatment of neurodegenerative diseases

Publications (1)

Publication Number Publication Date
GB0610183D0 true GB0610183D0 (en) 2006-06-28

Family

ID=36660655

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0610183.6A Ceased GB0610183D0 (en) 2006-05-23 2006-05-23 Treatment of neurodegenerative diseases

Country Status (2)

Country Link
GB (1) GB0610183D0 (en)
WO (1) WO2007135426A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9255266B2 (en) 2009-05-06 2016-02-09 Rutgers, The State University Of New Jersey RNA targeting in alpha-synucleinopathies
EP2380595A1 (en) 2010-04-19 2011-10-26 Nlife Therapeutics S.L. Compositions and methods for selective delivery of oligonucleotide molecules to specific neuron types
JP6126009B2 (en) * 2010-11-17 2017-05-10 アイオーニス ファーマシューティカルズ， インコーポレーテッドＩｏｎｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． Regulation of α-synuclein expression
EP2721145A4 (en) * 2011-06-16 2014-12-10 Parkinson S Inst High through-put screening in skin fibroblasts with an alpha-synuclein triplication
WO2017087282A1 (en) 2015-11-18 2017-05-26 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting leucine-rich repeat kinase 2 (lrrk2) for the treatment of parkinsons disease
US10370667B2 (en) 2015-11-18 2019-08-06 Rosalind Franklin University Of Medicine And Science Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
WO2018080573A1 (en) * 2016-10-28 2018-05-03 Massachusetts Institute Of Technology Crispr/cas global regulator screening platform
TWI809004B (en) 2017-11-09 2023-07-21 美商Ionis製藥公司 Compounds and methods for reducing snca expression
EP3737759A1 (en) 2018-01-12 2020-11-18 Roche Innovation Center Copenhagen A/S Alpha-synuclein antisense oligonucleotides and uses thereof
MX2020007433A (en) 2018-01-12 2020-09-14 Bristol Myers Squibb Co Antisense oligonucleotides targeting alpha-synuclein and uses thereof.

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605249B2 (en) * 2002-11-26 2009-10-20 Medtronic, Inc. Treatment of neurodegenerative disease through intracranial delivery of siRNA
WO2005004794A2 (en) * 2003-06-09 2005-01-20 Alnylam Pharmaceuticals Inc. Method of treating neurodegenerative disease
DE602005015994D1 (en) * 2004-09-29 2009-09-24 Childrens Memorial Hospital siRNA-mediated gene silencing of alpha-synuclein

Also Published As

Publication number Publication date
WO2007135426A2 (en) 2007-11-29
WO2007135426A3 (en) 2008-01-31

Similar Documents

Publication Publication Date Title
EP2004204A4 (en) Treatment of neurodegenerative diseases
SI2044111T1 (en) Targeting complement factor h for treatment of diseases
HK1131047A1 (en) Treatment of inflammatory diseases
EP2182983A4 (en) Treatment of amyloidogenic diseases
ZA200707591B (en) Dihyrothienopyrimidines for the treatment of inflammatory diseases
IL200368A0 (en) Treatment of diseases characterized by inflammation
GB0602178D0 (en) Therapeutic treatment
GB0610867D0 (en) Treatment of pain
EP2068864A4 (en) Therapeutic uses of urolithins
IL197315A0 (en) Treatment of cancer
IL193748A0 (en) Treatment of pain
GB0610183D0 (en) Treatment of neurodegenerative diseases
SI2056863T1 (en) Treatment of ocular diseases
GB0608655D0 (en) Therapeutic Treatment
HK1148684A1 (en) Treatment of prion protein related diseases
GB0603181D0 (en) Treatment of neurodegenerative and psychiatric diseases
ZA200905364B (en) Treatment of diseases characterized by inflammation
GB0610909D0 (en) Therapeutic treatment
GB0610868D0 (en) Treatment of pain
GB0723100D0 (en) Treatment of HFnEF
GB0519274D0 (en) The treatment of neurodegenerative diseases
GB0622136D0 (en) Treatment of gastrointestinal diseases
GB0623740D0 (en) Treatment of disease
GB0611417D0 (en) Treatment of cndaria intoxication
GB0616450D0 (en) Treatment of pain

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)